Multiple sclerosis is a progressive disease at the biological level, even when it does not look that way on the surface. The old textbook picture divided MS into tidy categories: relapsing-remitting, secondary progressive, and primary progressive, as if these were separate conditions that a person might switch between at defined moments. Contemporary research has dismantled that framework. Experts now describe MS as a single disease spectrum in which the same underlying mechanisms operate from the start, with inflammation and neurodegeneration running in parallel rather than in sequence.
The Spectrum View of MS
For decades, clinicians treated MS as though it came in phases: first a relapsing stage marked by attacks and recovery, then, for many people, a gradual shift into a progressive stage where disability crept upward without clear relapses. That framing was useful for clinical trials and drug approvals, but it created a misleading impression that progression was something that “happened later.” A growing body of evidence supports a different model: MS is better understood as a continuous spectrum, with inflammatory relapses and silent neurodegeneration overlapping throughout the disease course.
An expert advisory panel recently endorsed this paradigm shift, concluding that accumulated evidence supports moving away from distinct clinical phenotypes toward a continuum of clinical manifestations explained by the same underlying biological mechanisms.1PubMed Central. Towards a biological view of multiple sclerosis from early subtle to clinical progression: an expert opinion A separate review framed it similarly, describing MS as having “an admixture of interdependent and dynamic” biological processes driving tissue injury, rather than sequential disease phases.2PubMed Central. Understanding multiple sclerosis as a disease spectrum: above and below the clinical threshold
This matters practically because it changes how early you should worry about progression and how aggressively doctors might treat the disease from the outset. If progression starts from day one, waiting for a person to “convert” to secondary progressive MS before acting means years of damage have already accumulated silently.
Progression Starts Earlier Than Most People Think
One of the most striking findings of recent years is that disability can worsen independently of relapses, even in people who appear to have the relapsing-remitting form of the disease. Researchers call this PIRA, for progression independent of relapse activity. It is exactly what it sounds like: a slow, steady worsening of function that does not follow a relapse. It just creeps in.
A large real-world cohort study of over 5,000 people with early relapsing-onset MS found that PIRA accounted for roughly 61% of the first confirmed disability worsening events. These events were already detectable in the first years after diagnosis and became more common than relapse-associated worsening starting from the second year of follow-up.3Brain. Progression is independent of relapse activity in early multiple sclerosis: a real-life cohort study In a separate study of over 1,100 patients followed from their very first demyelinating event, about one in four developed PIRA over a median follow-up of roughly seven years. Those who experienced early PIRA had an eightfold greater risk of reaching a level of disability requiring a walking aid compared with those who did not have PIRA at all.4JAMA Neurology. Association of Early Progression Independent of Relapse Activity With Long-term Disability After a First Demyelinating Event in Multiple Sclerosis
The practical takeaway is clear: relapses are the visible part of MS, the tip of the iceberg. The bulk of disability accumulation over a lifetime may be driven by the invisible, smoldering processes underneath. Two people can have identical relapse histories and very different disability outcomes, depending on how much silent progression is happening in the background.
What Drives Progression Biologically
The visible attacks in MS are driven largely by immune cells crossing the blood-brain barrier, inflaming white matter, and damaging the myelin sheath around nerve fibers. Progression involves a different and more insidious set of processes. Three interrelated mechanisms stand out in the research.
First, chronic inflammation that never fully switches off. In the brains of people with progressive MS, clusters of immune cells, particularly B cells, can form organized structures in the membranes lining the brain. These meningeal B-cell follicles were detected in over 40% of secondary progressive MS cases in one autopsy study. Cases with these follicles had earlier disease onset, earlier disability, and more severe damage to the outer layers of the brain compared with those without follicles.5Brain. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology Another study linked meningeal B cells to altered behavior of microglia, the brain’s resident immune cells, in a way that was associated with neurodegeneration in the cortex.6bioRxiv. Meningeal inflammation in multiple sclerosis induces phenotypic changes in cortical microglia that differentially associate with neurodegeneration
Second, chronic active lesions. On MRI, some MS lesions develop a rim of activated microglia and macrophages that slowly expand outward, causing ongoing damage long after the initial attack. These are called paramagnetic rim lesions (PRLs) because the iron in those activated immune cells shows up on specialized MRI scans. A systematic review of five studies found that the presence of PRLs was associated with roughly double the odds of disability progression through PIRA.7PubMed. Paramagnetic iron rim lesions as a prognostic factor for disability progression in multiple sclerosis: A systematic review of the literature On the encouraging side, when existing PRLs resolved or new ones failed to appear, clinical outcomes improved.8PubMed Central. Associations Between Paramagnetic Rim Lesion Evolution and Clinical and Radiologic Disease Progression in Persons With Multiple Sclerosis
Third, energy failure in nerve cells. In progressive MS, the mitochondria inside neurons, the tiny structures that generate the cell’s fuel, become dysfunctional. The most consistently replicated finding involves deficiencies in the respiratory chain complexes that produce ATP, the molecule cells use for energy. Demyelinated axons need more energy than normal to conduct signals, and they are getting less of it. This mismatch between rising energy demand and falling energy supply is a major contributor to irreversible nerve fiber degeneration, especially in the long nerve tracts like the corticospinal pathways that control movement.9PubMed. Mitochondrial dysfunction and axon degeneration in progressive multiple sclerosis10PubMed Central. Mitochondrial Dysfunction and Multiple Sclerosis
How Aging Accelerates the Process
MS is most likely to adopt a clearly progressive clinical course during middle age and beyond, regardless of when the disease started. That observation has led researchers to investigate whether aging itself is a driver of progression, not just a backdrop.
The answer appears to be yes. Both immune aging and brain aging contribute. As the immune system ages, it becomes less efficient at repairing damage and more prone to chronic, low-grade inflammation. In the brain, aging reduces the capacity of the cells that form new myelin (oligodendrocytes), weakens the blood-brain barrier, and accelerates the kind of cellular senescence that promotes a persistently inflammatory environment.11Frontiers in Cellular Neuroscience. Aging, Cellular Senescence, and Progressive Multiple Sclerosis A review in The Lancet Neurology argued that the poor response of progressive MS to current therapies may be partly explained by these aging-related changes in the immune system and central nervous system, and that understanding aging could be key to halting non-relapse-related progression.12The Lancet Neurology. The ageing immune system and brain in multiple sclerosis
This is one reason researchers have grown more interested in biological aging markers in people with MS. The number of older adults living with MS is steadily increasing, and this population faces compounding disadvantages: the disease itself, the cumulative damage it has already caused, and the body’s declining ability to compensate.13PubMed Central. Biological aging in multiple sclerosis
Sex Differences in How Progression Unfolds
Women are two to three times more likely than men to develop MS. But men who do develop it tend to fare worse. Studies consistently show that men with MS accumulate disability faster, experience greater brain atrophy, and have more cognitive impairment than women with the same disease duration.14PubMed. Sexual disparities in the incidence and course of MS The greater neurological progression seen in males correlates with more chronic immune activation, more iron accumulation at the edges of chronic white-matter lesions, and more pronounced loss of gray matter.15PubMed Central. Potential biological contributers to the sex difference in multiple sclerosis progression
Structural brain imaging backs this up. One study found that while both men and women with MS showed deep gray matter atrophy in the thalamus, men had additional atrophy in the putamen and in localized cortical regions. Men also performed worse on tests of upper-limb dexterity, and there was a strong correlation between thalamic volume and hand function in men that was not present in women.16PubMed Central. Sex differences in brain atrophy in multiple sclerosis The reasons for this disparity are still being worked out, but sex hormones, differences in immune regulation, and possibly X-chromosome-linked factors all likely play a role.
Tracking Progression With Blood Tests and Imaging
One major challenge with silent progression is detecting it. You cannot treat what you cannot see. Two newer biomarkers have drawn attention for their potential to flag progression before it becomes clinically obvious.
Neurofilament light chain (NfL), a protein released when nerve fibers are damaged, can be measured in a simple blood draw. It is a reasonable marker of acute inflammatory damage and relapses. But for predicting slower, smoldering progression, a different blood marker may be more useful: glial fibrillary acidic protein (GFAP), which reflects injury or activation of astrocytes, the brain’s main support cells. One study found that a doubling of baseline GFAP in the blood was associated with nearly a fourfold increase in the risk of future PIRA, outperforming NfL as a predictor of progression.17JAMA Neurology. Serum Glial Fibrillary Acidic Protein Compared With Neurofilament Light Chain as a Biomarker for Disease Progression in Multiple Sclerosis A second study in people with progressive MS confirmed that higher GFAP was tied to a greater risk of confirmed disability progression, particularly in patients with low NfL and without recent inflammatory activity, exactly the group where silent progression is hardest to detect.18PubMed Central. Serum GFAP and NfL Levels Differentiate Subsequent Progression and Disease Activity in Patients With Progressive Multiple Sclerosis
On the imaging side, spinal cord atrophy is turning out to be one of the most powerful early warning signs. A study found that people who eventually transitioned to secondary progressive MS showed faster spinal cord shrinkage at least four years before the clinical conversion was recognized, losing cord volume at more than twice the rate of matched relapsing-remitting patients.19PubMed Central. Spinal Cord Atrophy Predicts Progressive Disease in Relapsing Multiple Sclerosis A meta-analysis confirmed that the spinal cord shrinks faster in progressive forms of MS than in relapsing forms, and that spinal cord atrophy rates actually exceed brain atrophy rates in MS, making it a highly relevant measurement.20PubMed. Spinal Cord Atrophy in Multiple Sclerosis: A Systematic Review and Meta-Analysis
What Treatments Can Do for Progressive MS
Treating relapsing MS has become dramatically effective over the past two decades. Treating progressive MS remains much harder, because the processes driving silent neurodegeneration are partly trapped behind the blood-brain barrier, where many drugs do not reach well. Still, two approved therapies have shown measurable effects.
Ocrelizumab, a B-cell-depleting antibody, is the only treatment approved specifically for primary progressive MS. In the pivotal trial, it reduced the risk of confirmed disability progression at 12 weeks by about 24% compared with placebo, and it slowed worsening on a timed walking test and reduced brain lesion volume.21PubMed. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis Follow-up analyses suggest that higher drug exposure was associated with greater reductions in disability progression, supporting the idea that B-cell depletion has a dose-dependent effect on the disease.22PubMed Central. Association of Higher Ocrelizumab Exposure With Reduced Disability Progression in Multiple Sclerosis Beyond its anti-inflammatory effects, emerging evidence suggests ocrelizumab may slow brain atrophy and reduce neurofilament levels partly independently of suppressing overt inflammatory activity, hinting at some effect on the smoldering component.23PubMed Central. Does Ocrelizumab Limit Multiple Sclerosis Progression? Current Evidence from Clinical, MRI, and Fluid Biomarkers
Siponimod, approved for secondary progressive MS, works differently: it traps certain immune cells in lymph nodes so they cannot reach the brain. In the large EXPAND trial and its extension, continuous siponimod treatment reduced the risk of six-month confirmed disability progression by about 22% over more than five years.24PubMed Central. Long-term efficacy and safety of siponimod in patients with secondary progressive multiple sclerosis: Analysis of EXPAND core and extension data up to >5 years It also showed a notable effect on cognitive processing speed, with treated patients scoring meaningfully better on a standard cognitive test than those on placebo over two years.25PubMed. Siponimod and Cognition in Secondary Progressive Multiple Sclerosis: EXPAND Secondary Analyses Real-world data from a prospective study has supported the trial findings, showing stabilization of disability and cognitive scores during follow-up.26PubMed Central. Impact of Siponimod on Clinical and Radiological Parameters of Secondary Progressive Multiple Sclerosis: A Real-World Prospective Study
Neither drug halts progression entirely. Both slow it, which is an important distinction. Patients and families should understand that slowing a decline is medically meaningful, but it is not the same as stopping it.
BTK Inhibitors and the Push to Treat Smoldering Disease
The next frontier in progressive MS treatment targets the smoldering inflammation inside the brain that current drugs do not fully reach. Bruton’s tyrosine kinase (BTK) inhibitors are a class of drugs that can cross the blood-brain barrier and act on both B cells and microglia within the central nervous system, making them a potentially better fit for the chronic active lesions that drive silent progression.27PubMed Central. Beyond relapses: How BTK inhibitors are shaping the future of progressive MS treatment
Preclinical and cell-based studies have been encouraging. One study using human stem-cell-derived microglia showed that BTK inhibition modulated neuroinflammatory pathways relevant to MS and that BTK was expressed at increased levels in MS brain lesions.28Nature Communications. BTK regulates microglial function and neuroinflammation in human stem cell models and mouse models of multiple sclerosis Another study on fenebrutinib, a specific BTK inhibitor, demonstrated that the drug could dampen the type of microglial activation associated with chronic active lesions and paramagnetic rim lesions, the exact pathology linked to progression.29PubMed Central. Fenebrutinib, a Bruton’s tyrosine kinase inhibitor, blocks distinct human microglial signaling pathways
Multiple BTK inhibitors are in late-stage clinical trials. Results so far have been mixed, with some trials missing their primary endpoints, but the field remains optimistic that this class of drugs may address a gap no current treatment fills. The hypothesis is straightforward: if you can quiet the microglia that keep chronic active lesions expanding, you might slow the smoldering neurodegeneration that drives long-term disability.
Does “Benign MS” Really Stay Benign?
Some people with MS accumulate little or no disability over many years. The label “benign MS” has traditionally been applied to those who maintain a low disability score after 15 or more years of disease. This raises an obvious question: is MS always progressive, or can it genuinely stay mild for a lifetime?
The evidence here is sobering. In a long-term follow-up of patients initially classified as benign at 10 years, an appreciable proportion later worsened, leading researchers to conclude that neither the standard disability thresholds at 10 years nor even at 15 years reliably identified people who would remain mild.30PubMed. Longitudinal follow-up of benign multiple sclerosis at 20 years A 30-year follow-up of patients who were benign at 15 years found that roughly three-quarters still met the benign threshold at 20 years, but by 30 years the proportion had dropped further. Even among those who remained physically benign by conventional measures, the hidden burden was significant: half reported fatigue, about a quarter had depression, and a striking 83% showed cognitive impairment on testing.31PubMed Central. Benign multiple sclerosis and long-term outcomes after 30 years
A nationwide cohort study confirmed that patients with benign MS do progress more slowly as a group, but the label provides uncertain reassurance for any individual.32Journal of Neurology, Neurosurgery & Psychiatry. Factors associated with and long-term outcome of benign multiple sclerosis: a nationwide cohort study “Benign” based on a walking disability score misses cognitive decline, fatigue, and other symptoms that profoundly affect daily life. So yes, there are gentler trajectories, but calling MS truly non-progressive in anyone is something even the most optimistic researchers are reluctant to do.
Age of Onset and How It Shapes the Course
Pediatric-onset MS behaves differently from adult-onset disease, but not in the way you might expect. Children and teenagers who develop MS tend to have more frequent relapses and a more inflammatory-looking disease, but they accumulate physical disability more slowly in the early years. The catch is that they reach significant disability milestones at a younger absolute age, simply because the clock started ticking sooner.33PubMed Central. Long-term disability progression of pediatric-onset multiple sclerosis
People diagnosed later in life, on the other hand, show steeper disability trajectories when PIRA occurs. A study comparing pediatric-onset, adult-onset, and late-onset MS found that when PIRA happened, the increase in disability scores was most dramatic in the late-onset group and least dramatic in the pediatric-onset group.34PubMed Central. Disability trajectories by progression independent of relapse activity status differ in pediatric, adult and late-onset multiple sclerosis This tracks with the aging story: older nervous systems have less reserve capacity, less ability to remyelinate, and a more senescent immune environment, all of which amplify the impact of each progressive event.
Smoking, Exercise, and What You Can Influence
Among modifiable risk factors, smoking is the most consistently linked to worse progression. People with MS who smoke show higher rates of disease activity, faster brain atrophy, and greater overall disability burden.35JAMA Neurology. Association Between Cigarette Smoking and Multiple Sclerosis: A Review The mechanisms likely involve both direct toxic effects on the nervous system and additional stimulation of immune pathways that are already overactive. Quitting does not reverse existing damage, but the evidence strongly suggests it can slow the rate at which new damage accumulates.36PubMed Central. The effect of smoking on the symptoms and progression of multiple sclerosis: a review
Exercise is harder to study rigorously in progressive MS, but the available evidence supports a role in managing symptoms if not the disease biology itself. A trial of structured exercise training in people with progressive MS found significant reductions in physical and psychosocial fatigue, though it did not significantly change scores on functional ability measures or overall quality-of-life scales.37International Journal of MS Care. Exercise Training in Progressive Multiple Sclerosis That result may sound underwhelming, but in a disease where fatigue is one of the most disabling everyday symptoms, a training program that reliably reduces it is worth pursuing.
Machine Learning and Predicting Who Will Progress
If progression is happening silently in many patients, can we predict who will progress fastest? Machine learning models trained on routinely collected clinical data are beginning to show that yes, the patterns are there. One international, multi-center study demonstrated good ability to predict future progression using only the kind of variables already available in clinic records, and concluded the models were mature enough for a clinical impact study.38PLOS Digital Health. Machine-learning-based prediction of disability progression in multiple sclerosis: An observational, international, multi-center study
A separate effort built models to predict conversion to secondary progressive MS and rapid disability accumulation at six and ten years. Using data from the first two years after diagnosis, the model predicted conversion to secondary progressive disease with strong accuracy, and predicted rapid disability accumulation at six years with similarly strong performance.39Scientific Reports. Prediction of disease progression and outcomes in multiple sclerosis with machine learning These tools are not in routine clinical use yet, but they represent a shift toward personalized risk profiles that could help clinicians decide when to escalate treatment rather than waiting until disability becomes obvious.